The European Patent Office (EPO) has published patent application EP4514797A1, detailing substituted 7-(pyrimidin-4-yl)quinolin-4(1H)-one compounds designed as cyclin-dependent kinase inhibitors. The application, filed by BeOne Medicines I GmbH, includes specific chemical structures and their potential application in treating diseases, particularly cancer, as indicated by the A61P 35/00 classification.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it signifies potential future intellectual property rights and market exclusivity for the applicant in the specified jurisdictions. Companies operating in the pharmaceutical and biotechnology sectors should be aware of this filing as it pertains to novel drug candidates and potential competitive landscape shifts.